Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 3/20 | 0.49 |
| ▸ | AVPR1A | P37288 | 17/20 | 0.42 |
| ▸ | OXTR | P30559 | 6/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21397115 | 0.83 | TSPO (0.55) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL21396930 | 0.83 | TSPO (0.54) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL20277316 | 0.78 | TSPO (0.49) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL26564452 | 0.78 | TSPO (0.49) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL20277707 | 0.77 | TSPO (0.53) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL20277736 | 0.77 | TSPO (0.48) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL26564518 | 0.76 | TSPO (0.48) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL26564832 | 0.76 | TSPO (0.48) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL26564333 | 0.75 | TSPO (0.52) | TSPOAVPR1AOXTRAVPR2 | |
| SCHEMBL2628443 | 0.75 | TSPO (0.58) | TSPOAVPR1AOXTRAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | OXTR, AVPR1B, AVPR1A | TSPO 478/4885AVPR1A 3/4885OXTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.